

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PCT/PTO 17 SEP 2001

#5

In re Application of
MARCIREAU ET AL.

Examiner: UNASSIGNED

Art Unit: UNASSIGNED

Serial No.: **09/744,125**

Filed: JANUARY 19, 2001

Title: **MEKK1-INTERACTING FHA
PROTEIN (M1F1)**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
regular mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

September 13, 2001

Date of Deposit

Signature

Kapadia

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

William C. Coppola

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Docket No. A3233A US